Deep Intelligent Pharma Files IPO Prospectus Highlighting Blockchain-Enabled AI Platform for End-to-End Drug Development
DeepBioscience is composed of senior experts from multinational pharmaceutical companies such as Johnson & Johnson, Pfizer, Eli Lilly, and Novartis, together with top AI algorithm specialists from Alibaba and leading NLP experts from the Natural Language Processing Laboratory at Northeastern University. It is a rare AI-driven innovative enterprise for new drug R&D that is truly led by pharmaceutical experts with deep business acumen. A profound understanding of user pain points is a critical factor in the successful application of AI to new drug development. Within just six months of its establishment, the company has already delivered multiple use cases for multinational pharmaceutical firms. We believe DeepBioscience will grow into a leading company in AI-enabled new drug R&D, bringing hope to patients.
—— Deep Wisdom Investor
Yin Le, Vice President of Investment at ZhenFund
Recently, DeepIntel, an AI-driven new drug R&D company, announced that it secured exclusive pre-A round financing of several million US dollars from ZhenFund in December 2017. The integration of artificial intelligence and blockchain technology will empower the entire process of new drug research and development.
Beijing Deepwise Technology Co., Ltd. was founded in Beijing in October 2017. It is an international startup that leverages cutting-edge artificial intelligence and blockchain technologies to empower the entire lifecycle of new drug development, regulatory submission, and post-marketing processes. The company is committed to building an end-to-end AI-driven platform for new drug discovery and development, enabling and accelerating pharmaceutical companies worldwide to efficiently and effectively bring drugs from the laboratory to the market with high quality.
DeepBios is a disruptive innovator in the industry. Within just six months of its establishment, it has launched ten products and established use cases with the global headquarters, Asia-Pacific divisions, and China offices of multiple multinational pharmaceutical companies, as well as leading domestic pharmaceutical enterprises. DeepBios is continuously leveraging AI to integrate more stages of new drug development, demonstrating group-level collaborative capabilities and pioneering an innovative path rarely traversed by others.
Currently, DeepIntellect operates and conducts R&D simultaneously in China and the United States. Headquartered in Beijing, the company has offices in Shanghai, Shenyang, Boston, Silicon Valley, and other locations, with an artificial intelligence laboratory established in Shenyang. The company currently employs more than 50 full-time staff members.
New drug development is a protracted process. Bringing a new drug from the laboratory to market requires ten years, 100 scientists, and $2.7 billion, with a success rate of less than 7%. Currently, only 5,000 diseases are curable, while 8,000 remain incurable. Therefore, the current organizational model for new drug development fails to meet demand. Global new drug development is still reliant on labor-intensive strategies and lacks AI integration. As the pharmaceutical industry undergoes profound transformation, pharmaceutical companies that fail to deploy AI face the risk of elimination in the future.
It is reported that the product lines Deepwise has already launched or is currently rolling out in 2018 include: intelligent medical writing, the world’s leading multilingual medical machine translation and high-end human medical translation services, a globally leading knowledge graph for new drug R&D, an AI-driven decision-making brain for new drug development, AI-powered medical education, intelligent regulatory affairs, intelligent pharmacovigilance, a blockchain-based patient treatment research ecosystem, and an intelligent rare disease research platform. Among these, eight products have established use cases with multinational pharmaceutical companies.